The scientific efforts led by Salvemini, who is professor of pharmacological and physiological sciences at SLU, demonstrated that turning on a receptor in the brain and spinal cord counteracts chronic nerve pain in male and female rodents. Activating the A3 receptor—either by its native chemical stimulator, the small molecule adenosine, or by powerful synthetic small molecule drugs invented at the NIH—prevents or reverses pain that develops slowly from nerve damage without causing analgesic tolerance or intrinsic reward (unlike opioids).

Pain is an enormous problem. As an unmet medical need, pain causes suffering and comes with a multi-billion dollar societal cost. Current treatments are problematic because they cause intolerable side effects, diminish quality of life and do not sufficiently quell pain.

The most successful pharmacological approaches for the treatment of chronic pain rely on certain "pathways": circuits involving opioid, adrenergic, and calcium channels.

For the past decade, scientists have tried to take advantage of these known pathways—the series of interactions between molecular-level components that lead to pain. While adenosine had shown potential for pain-killing in humans, researchers had not yet successfully leveraged this particular pain pathway because the targeted receptors engaged many side effects.

In this research, Salvemini and colleagues have demonstrated that activation of the A3 adenosine receptor subtype is key in mediating the pain relieving effects of adenosine.

"It has long been appreciated that harnessing the potent pain-killing effects of adenosine could provide a breakthrough step towards an effective treatment for chronic pain," Salvemini said. "Our findings suggest that this goal may be achieved by focusing future work on the A3AR pathway, in particular, as its activation provides robust pain reduction across several types of pain."

Researchers are excited to note that A3AR agonists are already in advanced clinical trials as anti-inflammatory and anticancer agents and show good safety profiles. "These studies suggest that A3AR activation by highly selective small molecular weight A3AR agonists such as MRS5698 activates a pain-reducing pathway supporting the idea that we could develop A3AR agonists as possible new therapeutics to treat chronic pain," Salvemini said.

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Evidence Young People Are Turning to Christianity Isn’t Anecdotal; It’s Real

100 Missionaries Deploy to 10/40 Window amid Increasing Reports of Visions of 'The Man in White'

WATCH: Millionaire Tax Critic Says AGO, Dems Played Politics Instead of Protecting Residents

Total Victory: Florida Congressional Maps Are Now Official

Trump, Hegseth Praise US Performance in Iran as Congress Pushes Back; Israel Appalled at London Attack on Jews

Ex-Muslim Flees Iran, Says Jesus Appeared in Dreams to Family Members

May Day Protests are Coming. Urgent Prayers Needed!

Anthony Fauci's Former Senior Adviser Indicted for Role in COVID Cover-up

King Charles III Gifts President a Bell from Hms Trump at White House State Dinner Reinforcing US-UK Bonds

Feds Raid More Than 20 Sites in Minneapolis Fraud Probe

This is a Spiritual Battle over America; Take Your Place Praising God, Our Worship is Warfare!

#1 NFL Draft Pick Praises God: 'I Just Can't Thank Him Enough'

UK Pastor Prosecuted for Preaching John 3:16 Anxiously Awaiting Judge's Ruling

Renowned Bible Teacher and Evangelist Marilyn Hickey Passes On to Eternity

Oz Pearlman Reveals What Was Written on Card Shown to President Trump during WH Correspondents' Shooting

After the Shooting, Democrat Senator Fetterman Backs the White House Ballroom Renovation

Blockade Effect: Iran's Regime Has DAYS Until This Crisis Hits

Kenya Court Overturns 'Constitutional Right' to Abortion in Pro-Life Victory

Give Him 15: 'It's Time to Tip the Scale'

Surprising Bible Find Sparks Big 'Opportunity' For the Church